Cellarity’s mission is to fundamentally redesign the way drugs are created for the sake of bringing new hope to patients. By shifting the focus from a single target to the underlying cellular dysfunction, we unravel the complexity of disease biology and create medicines that were never before possible. The company has developed unique capabilities that link biology and chemistry with high dimensional -omic data from which we design medicines against the cellular signature of disease. The Cellarity platform allows us to uncover new biology in diseases even in the absence of known causal targets. Cellarity is a privately held, clinical-phase drug discovery startup using AI and single-cell omics to develop life-changing medicines that are unreachable by traditional methods of drug discovery. Cellarity is a product of Flagship Pioneering's venture creation engine, which has conceived and created companies such as Moderna (NASDAQ: MRNA), Generate: Biomedicines, and Lila Sciences.